Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
LaFleur Minerals Announces MOU with Granada Gold on Milling Assessment (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Avenue Therapeutics Inc
ATXI
Healthcare
Biotechnology
Drug Manufacturers - Specialty & Generic
Avenue Therapeutics, Inc. is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases. The Company is developing three assets including AJ201, an asset for spinal and bulbar muscular atrophy; BAER-101, an oral small molecule selective Gamma-aminobutyric acid receptor A alpha 2 & 3 (GABAA a2, a3) receptor positive...
allosteric modulator for central nervous system (CNS) diseases; and IV tramadol, which is in phase III clinical development for the management of acute postoperative pain in adults in a medically supervised healthcare setting. AJ201 is a pleiotropic small molecule that is designed to modify multiple mechanisms including degradation of the abnormal AR protein and stimulation of Nrf1 and Nrf2, which are involved in protecting cells form oxidative stress which can lead to cell death. Tramadol, a synthetic dual-acting opioid, is a centrally acting analgesic with weak opioid agonist properties.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (OTCPK:ATXI)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
Next
(0)
•••
PressRelease
X
Post by
PressRelease
on Oct 12, 2022 10:25am
New Press Release - Aegis Capital Corp. Acted as Sole Bookrunner on a $12 Million Underwritten Public Offering for Avenue Therapeutics, Inc. (NASDAQ:ATXI)
NEW YORK, NY / ACCESSWIRE / October 12, 2022 / Aegis Capital Corp. acted as Sole Bookrunner on a $12 Million Underwritten Public Offering for Avenue Therapeutics, Inc. (NASDAQ:ATXI).About Avenue Therapeutics, Inc.Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and...
read article.
(82)
•••
Iseneschal
X
Post by
Iseneschal
on Oct 11, 2022 3:50pm
ATXI ..... Sold to all the Chasers
Tomorrows another day I switching focus to NBRV Cheers !
LaFleur Minerals Announces MOU with Granada Gold on Milling Assessment
posted Mar 27, 2025 9:00am by
LaFleur Minerals Inc.
-
|
The agreement solidifies LaFleur's position and plans to become a near-term producer, as it now has proven support, through potential partnership, to cater to regional players for custom milling operations - this MOU validates the future commercial viability of the Beacon Mill and additionally mitigates operational risk ...read more
(82)
•••
Iseneschal
X
Post by
Iseneschal
on Oct 11, 2022 3:39pm
ATXI ..... well Maddapakkas....How do you like me so far ???
$2.94 & H.O.D
(82)
•••
Iseneschal
X
Post by
Iseneschal
on Oct 11, 2022 2:26pm
ATXI ..... Ok u Maddapakkas..... Here's another gift horse !
Needs to break $3.05 and this is gone to the Moon Kiss my a$$
(0)
•••
PressRelease
X
Post by
PressRelease
on Oct 11, 2022 2:15pm
New Press Release - Avenue Therapeutics Announces Closing of $12 Million Underwritten Public Offering
NEW YORK, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of central nervous system diseases, today announced the closing of...
read article.
(82)
•••
Iseneschal
X
Post by
Iseneschal
on Oct 10, 2022 1:39pm
ATXI ...... LMFAO
Keep up the good work !
(82)
•••
Iseneschal
X
Post by
Iseneschal
on Oct 10, 2022 1:06pm
ATXI ..... Hey Mr. Maggot..... My position is green LoL
Time for a "shake out " ??? Cheers !
(82)
•••
Iseneschal
X
Post by
Iseneschal
on Oct 10, 2022 12:52pm
ATXI ...... all eyes on the next target ; )
Anyone curious ? He he
(82)
•••
Iseneschal
X
Comment by
Iseneschal
on Oct 10, 2022 12:49pm
RE:ATXI ....get ready for the Maggot Dump ; )
That post was a Bullsh8t post LMFAO.....you can't handle the truth and good info....so I just fed Mr. Maggot the paper I bot at the low this a.m What a game....If nobody likes my posts...
...more
(82)
•••
Iseneschal
X
Post by
Iseneschal
on Oct 10, 2022 12:30pm
ATXI ....get ready for the Maggot Dump ; )
Cheers !
(82)
•••
Iseneschal
X
Post by
Iseneschal
on Oct 10, 2022 11:09am
ATXI ..... Mr. Maggot wants to "shake" you all out ; )
Keep your "powder keg" dry U just might need it Cheers !
(82)
•••
Iseneschal
X
Comment by
Iseneschal
on Oct 07, 2022 2:07pm
RE:ATXI ...... Big gap to fill above $2.70 ...just sayin ; )
Boy .....you guys are a tough audience to please. Why don't u take a moment and start liking my posts? I'd like to build up my reputation score..... what do you think? Do I deserve a higher
...more
(82)
•••
Iseneschal
X
Post by
Iseneschal
on Oct 07, 2022 10:13am
ATXI ...... Big gap to fill above $2.70 ...just sayin ; )
I can only imagine how big the Short Position is on the deal !!!! Remember.......the bigger the Short Position....the faster the ramp up ; ) Cheers !
(0)
•••
PressRelease
X
Post by
PressRelease
on Oct 06, 2022 11:00pm
New Press Release - Avenue Therapeutics Announces Pricing of $12 Million Underwritten Public Offering
NEW YORK, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of central nervous system diseases, today announced the pricing of...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Oct 03, 2022 8:00am
New Press Release - Urica Therapeutics Appoints Seasoned Biotech Executive Jay D. Kranzler, M.D., Ph.D., as Chairman and Chief Executive Officer
Company also strengthens Board of Directors with addition of Stanford Professor Vibeke Strand, M.D., MACR, FACP MIAMI, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. (“Urica” or the “Company”) (formerly known as UR-1 Therapeutics, Inc.), a Fortress Biotech, Inc. (Nasdaq: FBIO...
read article.
Prev
1
2
3
4
5
6
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Crypto Insights at Your Fingertips – View Now!
GBC AG Investment Research Analyst Report Indicates Strong Growth Forecast for DynaCert
Expanding opportunity: The re-refined Group III market represents less than 1% of the industry
The Value Play: Invest in One of the Largest Gaming Media Networks in North America
Critical Mineral Executive Order Issued by President Donald Trump